Latest Psoriasis Stories

A population-based study from the United Kingdom suggests that the common skin condition psoriasis may be a risk factor for the development of Type 2 diabetes mellitus (T2DM), according to a report published Online First by Archives of Dermatology, a JAMA Network publication. Psoriasis, a chronic inflammatory disease characterized by scaling of the skin, affects 2 percent to 4 percent of the adult population, according to the study background. Rahat S. Azfar, M.D., of the University of...

BALLERUP, Denmark, June 14, 2012 /PRNewswire/ -- LEO Pharma is now actively searching for new global or territorial partners to deliver promising new compounds for its dermatology-focused pipeline. Corporate VP hopes to sign two or more new deals before the end of 2012. (Logo: http://photos.prnewswire.com/prnh/20120614/537969-a ) (Photo: http://photos.prnewswire.com/prnh/20120614/537969-b ) (Photo: http://photos.prnewswire.com/prnh/20120614/537969-c )...

NORWALK, Conn., June 13, 2012 /PRNewswire/ -- UBM Medica US today announced that Musculoskeletal Network, an online resource for unique and efficient techniques on the management of musculoskeletal disorders, now provides research highlights from the 2012 Annual Congress of the European League Against Rheumatism (EULAR), held in Berlin. EULAR's goal is to provide a forum for scientific, educational, and social exchange among professionals in rheumatology to achieve progress in the...

NEW YORK, June 11, 2012 /PRNewswire/ -- ArganOilShop.com today introduced Premium Cosmetic Argan, a natural cosmetic made of 100 percent pure argan oil, which has been used for centuries as a skin moisturizer and hair treatment by Berber women of Morocco because it is rich in Vitamin E. "Today we're seeing a huge movement to green cosmetics and natural skin care products. Women are eager to use products that are all natural," said Hicham ben Youssef of ArganOilShop.com. Argan oil...

Phase III study also demonstrates similar safety profile to placebo A new Phase III study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, shows that patients with active psoriatic arthritis (PsA) treated with Ustekinumab (UST) 90mg were more than twice as likely to achieve the study's primary endpoint, ACR20 at 24 weeks, than those treated with placebo (49.5% vs 22.8%). 42.4% of patients treated with UST 45mg were also more likely to achieve...

BERLIN and BRUSSELS, June 6, 2012 /PRNewswire/ -- Results from the RAPID(TM)-PsA study presented this week at the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology in Germany showed that certolizumab pegol compared to placebo improved the signs and symptoms of arthritis in adult patients with active psoriatic arthritis (PsA). "Certolizumab pegol has been shown to be clinically effective in moderate to severe rheumatoid arthritis. The RAPID(TM)-PsA...

VERONA, Italy, June 6, 2012 /PRNewswire/ -- New efficacy and safety data from the Phase 3 PHOENIX 1 study, one of two pivotal registration trials, showed that maintenance treatment with STELARA® (ustekinumab) for up to five years resulted in consistent, significant clinical response in adults with moderate to severe plaque psoriasis. Among responders receiving STELARA 45 mg or 90 mg and randomized to continue maintenance therapy through five years, 79 and 81 percent of patients,...

BERLIN, June 6, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) today announced results from the Phase 3 ABILITY-2 investigational study of HUMIRA® (adalimumab) in patients with active peripheral spondyloarthritis (PSpA) who have not been diagnosed with psoriatic arthritis (PsA) or ankylosing spondylitis (AS). At week 12, nearly twice as many HUMIRA patients compared to those receiving placebo achieved the primary endpoint, defined as at least a 40 percent improvement in the peripheral SpA...

BERLIN, June 6, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) today announced results from two long-term, open-label studies, which evaluated the results of HUMIRA® (adalimumab) treatment for up to 10 years in patients with long-standing, moderate-to-severe rheumatoid arthritis (RA). These 10-year HUMIRA studies, DE019 and DE020, are among the longest, open-label trials in RA. Results presented at the European League Against Rheumatism (EULAR) 2012 Congress in Berlin, Germany, include...

BERLIN, June 6, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) today announced results from the open-label extension of the Phase 3 ABILITY-1 investigational study of HUMIRA® (adalimumab), which assessed the improvement in signs and symptoms of disease for patients with active axial spondyloarthritis (axSpA) who have no X-ray evidence of structural damage. Results were presented at the European League Against Rheumatism (EULAR) 2012 Congress in Berlin, Germany. ABILITY-1 is the first...